Is it time to include oxygen needs as an endpoint in clinical trials in patients with fibrosing interstitial lung disease? If so, how?

Many patients with fibrosing interstitial lung disease (fILD) will need to use supplemental oxygen (O(2)) to maintain normoxia at some point in their illness. If it is not needed at the time of diagnosis, then if fILD progresses—or if a comorbid condition like pulmonary hypertension develops—O(2) wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Aronson, Kerri, Jacobs, Susan S, Repola, Dawn, Swigris, Jeffrey J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Perspective
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347448/
https://www.ncbi.nlm.nih.gov/pubmed/37419519
http://dx.doi.org/10.1136/bmjresp-2022-001546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347448/
https://www.ncbi.nlm.nih.gov/pubmed/37419519
http://dx.doi.org/10.1136/bmjresp-2022-001546

Ejemplares similares